92 related articles for article (PubMed ID: 2693107)
1. Current approaches to management of infections in bone marrow transplants.
Winston DJ; Ho WG; Champlin RE
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S25-35. PubMed ID: 2693107
[TBL] [Abstract][Full Text] [Related]
2. Prophylaxis and treatment of infection in the bone marrow transplant recipient.
Winston DJ
Curr Clin Top Infect Dis; 1993; 13():293-321. PubMed ID: 8397916
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of infection in bone marrow transplants.
Winston DJ; Ho WG; Gale RP; Champlin RE
Eur J Cancer Clin Oncol; 1988; 24 Suppl 1():S15-23. PubMed ID: 3127217
[TBL] [Abstract][Full Text] [Related]
4. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.
Winston DJ; Gale RP
Bone Marrow Transplant; 1991 Jul; 8(1):7-11. PubMed ID: 1655140
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
6. [Prevention and treatment of cytomegalovirus infections after graft of allogenic bone marrow].
Gluckman E; McMazeron ; Keable H; Meletis J; Bombail D; Jolivet I; Huart JJ; Nebout T; Cavazzana M; De Castro H
Nouv Rev Fr Hematol (1978); 1987; 29(1):17-21. PubMed ID: 3035485
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.
Atkinson K; Arthur C; Bradstock K; Dale B; Downs K; Gibson J; Golenia M; Ho J; Joshua D; Juttner C
Bone Marrow Transplant; 1995 Sep; 16(3):401-5. PubMed ID: 8535313
[TBL] [Abstract][Full Text] [Related]
8. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
Guglielmo BJ; Wong-Beringer A; Linker CA
Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
10. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
[TBL] [Abstract][Full Text] [Related]
11. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
12. The role of immunoglobulin in bone marrow transplantation.
Saral R
Transplant Proc; 1991 Aug; 23(4):2128-32. PubMed ID: 1871829
[TBL] [Abstract][Full Text] [Related]
13. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus infections after allogeneic bone marrow transplantation.
Winston DJ; Ho WG; Champlin RE
Rev Infect Dis; 1990; 12 Suppl 7():S776-92. PubMed ID: 2173107
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
Bass EB; Powe NR; Goodman SN; Graziano SL; Griffiths RI; Kickler TS; Wingard JR
Bone Marrow Transplant; 1993 Sep; 12(3):273-82. PubMed ID: 8241987
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
18. Post-transplant infections: single center experience from the developing world.
Ullah K; Raza S; Ahmed P; Chaudhry QU; Satti TM; Ahmed S; Mirza SH; Akhtar F; Kamal K; Akhtar FM
Int J Infect Dis; 2008 Mar; 12(2):203-14. PubMed ID: 17920999
[TBL] [Abstract][Full Text] [Related]
19. [Primary and secondary prevention of cytomegalovirus infections in immunocompromised patients].
Salmon-Céron D
Ann Med Interne (Paris); 1997; 148(3):246-54. PubMed ID: 9255334
[TBL] [Abstract][Full Text] [Related]
20. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
